Pelaia C, Crimi C, Pelaia G, et al. - Researchers assessed the impacts of mepolizumab in allergic as well as non allergic individuals with severe eosinophilic asthma in this observational study. A remarkable improvement in severe asthma, reported by a better symptom control, expressed by a significant betterment in asthma control test (ACT) score, was evident in 88 patients following one year of add‐on biological treatment with mepolizumab. An increment in the mean value (± standard deviation) of ACT score, from 12.55 (± 3.724) to 21.08 (± 3.358), was evident. Enhancement of forced expiratory volume in one second, from 1640 mL to 1920 mL, was noted, and a drop in blood eosinophil count, from 711.0 cells/µL to 90.00 cells/µL, was also detected. Additionally, a decline was evident in the annual rate of asthma exacerbations, which was from 3.000 to 0.000, and the daily prednisone consumption fell from 6.250 mg to 0.000 mg. Based on these real‐life data, it was concluded that mepolizumab can be a valid add‐on treatment choice for patients suffering from severe eosinophilic asthma, regardless of IgE serum levels and allergic sensitization.